Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi | Zendy

James Meiring | Zendy; Matthew B. Laurens | Zendy; Pratiksha Patel | Zendy; Priyanka Patel | Zendy; Theresa Misiri | Zendy; Kenneth Simiyu | Zendy; Felistas Mwakiseghile | Zendy; J. Kathleen Tracy | Zendy; Clemens Masesa | Zendy; Yuanyuan Liang | Zendy; Marc Henrion | Zendy; Elizabeth Rotrosen | Zendy; Markus Gmeiner | Zendy; Robert S. Heyderman | Zendy; Karen L. Kotloff | Zendy; Melita A. Gordon | Zendy; Kathleen M. Neuzil | Zendy

Open Access

Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi

Author(s) -

James Meiring,

Matthew B. Laurens,

Pratiksha Patel,

Priyanka Patel,

Theresa Misiri,

Kenneth Simiyu,

Felistas Mwakiseghile,

J. Kathleen Tracy,

Clemens Masesa,

Yuanyuan Liang,

Marc Henrion,

Elizabeth Rotrosen,

Markus Gmeiner,

Robert S. Heyderman,

Karen L. Kotloff,

Melita A. Gordon,

Kathleen M. Neuzil

Publication year - 2019

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy1103

Subject(s) - typhoid fever , medicine , reactogenicity , vaccination , immunogenicity , conjugate vaccine , typhoid vaccine , salmonella typhi , randomized controlled trial , pediatrics , immunology , virology , immune system , biochemistry , chemistry , escherichia coli , gene

Typhoid fever is an acute infection characterized by prolonged fever following the ingestion and subsequent invasion of Salmonella enterica serovar Typhi (S. Typhi), a human-restricted pathogen. The incidence of typhoid fever has been most reported in children 5-15 years of age, but is increasingly recognized in children younger than 5 years old. There has been a recent expansion of multidrug-resistant typhoid fever globally. Prior typhoid vaccines were not suitable for use in the youngest children in countries with a high burden of disease. This study aims to determine the efficacy of a typhoid conjugate vaccine (TCV) that was recently prequalified by the World Health Organization, by testing it in children 9 months through 12 years of age in Blantyre, Malawi.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research